AbbVie says lutikizumab met the Phase 3 endpoint in hidradenitis suppurativa, but results disappointed investors
AbbVie reported positive Phase 3 results for lutikizumab in the Intrepid trial for moderate-to-severe hidradenitis suppurativa. After 16 weeks, 31.4% of patients receiving weekly lutikizumab achieved at least a 75% reduction in inflamed bumps and abscesses,…
